Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes

Pharmacogenetics and Genomics

Volumn 18, Issue 12, 2008, Pages 1051-1057

  Knouff, Christopher W ^a   Lim, Noha ^a   Song, Kijoung ^a   Yuan, Xin ^a   Walker, Max C ^b   Townsend, Ray ^e   Waeber, Gerard ^f   Matthews, Paul M ^c,d   Vollenweider, Peter ^f   Waterworth, Dawn M ^a   Mooser, Vincent ^a,c  

^a Genetics Division

^b Metabolic Pathway Center of Excellence for Drug Discovery

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drugs; Genome wide association studies; Hypertension; Lipids; Population genetics; Single nucleotide polymorphisms; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTON PUMP INHIBITOR; TORCETRAPIB;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG TARGETING; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 57149126968     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32831270eb     Document Type: Article

References (23)

1. Spector R, Vesell ES. The heart of drug discovery and development: rational target selection. Pharmacology 2006; 77:85-92.
2. Roses AD, Burns DK, Chissoe S, Middleton L, St Jean P. Disease-specific target selection: a critical first step down the right road. Drug Discov Today 2005; 10:177-189.
3. Davey SG, Ebrahim S, Lewis S, Hansell AL, Palmer L J, Burton PR. Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005; 366:1484-1498.
4. Tarter TH, Vaughan ED Jr. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des 2006; 12:775-783.
5. Goldstein JL, Dana SE, Brunschede GY, Brown MS. Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Natl Acad Sci USA 1975; 72:1092-1096.
6. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Norton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514-523.
7. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007; 39:513-516.
8. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447:661-678.
9. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet 2008; 371:483-491.
10. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. alpha-5/ alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 2008; 13:368-373.
11. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al. Replicating genotype-phenotype associations. Nature 2007; 447:655-660.
12. Jorgenson E, Witte JS. Coverage and power in genome-wide association studies. Am J Hum Genet 2006; 78:884-888.
13. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358:1240-1249.
14. Marques-Vidal P, Pecoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, et al. Prevalence and characteristics of homeopathy users in a representative sample of the Lausanne population: CoLaus study. Pharmacoepidemiol Drug Saf 2008; 17:209-211.
15. Rodondi N, Cornuz J, Marques-Vidal P, Butler J, Hayoz D, Pecoud A, et al. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med 2008; 46:136-144.
16. Firmann M, Mayor V, Marques VP, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008; 8:6.
17. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515.
18. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
19. Patterson N, Price AL, Reich D. Population structure and eigen analysis. PLoS Genet 2006; 2:e190.
20. Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, et al. WGAViewer: Software for genomic annotation of whole genome association studies. Genome Res 2008; 18:640-643.
21. Wilier CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40:161-169.
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
23. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007; 370:1907-1914.